Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia
Open Access
- 1 February 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmacological Sciences
- Vol. 127 (2), 164-169
- https://doi.org/10.1016/j.jphs.2014.12.003
Abstract
No abstract availableKeywords
Funding Information
- Merck & Co, Inc., USA
- Faculty of Medicine
- Prince of Songkla University
This publication has 27 references indexed in Scilit:
- Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropeniaThe Lancet Infectious Diseases, 2008
- Two decades of imipenem therapyJournal of Antimicrobial Chemotherapy, 2006
- Use of Broad-Spectrum Antimicrobials for the Treatment of Pneumonia in Seriously Ill Patients: Maximizing Clinical Outcomes and Minimizing Selection of Resistant OrganismsClinical Infectious Diseases, 2006
- Heuristic random optimizationComputers & Chemical Engineering, 1998
- Pharmacokinetics of meropenem in febrile neutropenic patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patientsJournal of Chromatography B: Biomedical Sciences and Applications, 1997
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal ModelThe Journal of Infectious Diseases, 1988
- Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patientsAntimicrobial Agents and Chemotherapy, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976